ArticleClinical epidemiology2026

Cardiovascular Risks of Aromatase Inhibitors versus Tamoxifen in Postmenopausal Breast Cancer: A Multinational Cohort Study.

Shu-Chen Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.